51 results
6-K
OBSVF
ObsEva SA
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
the risks of such side effects for distribution to patients;
commitment to expensive additional safety studies prior to launch as a prerequisite … of approval by regulatory authorities of such product;
commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities
6-K
EX-99.1
OBSVF
ObsEva SA
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
. Wainwright & Co., as underwriter, has agreed to purchase on a firm commitment basis an aggregate of 6,448,240 units at an effective price of $2.869 per
6-K
EX-99.1
OBSVF
ObsEva SA
9 Nov 20
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
7:32am
would like to sincerely thank Dr Ernest
Loumaye for his steadfast leadership and commitment to ObsEva over the past seven years, developing ObsEva
6-K
jv72u0
15 Jan 20
Current report (foreign)
8:35pm
6-K
EX-99.1
nlo4q a9ofo
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
nhz20x3yg7hbre5
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
EX-99.1
cv15 2l41
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
7wjege8nqn012bfm498z
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
EX-99.1
i23g9iqv9
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
EX-99.1
n9pip3
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
8dpd1hjvsl09ivi52
27 Jul 21
Current report (foreign)
6:12am
6-K
4fy8mf9u3y gc0l52tgm
9 Oct 18
Current report (foreign)
4:42pm
6-K
EX-99.3
2r261rh9mhi2ck1o
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
1u5d1h4nq4
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
DRS
EX-10
nj250b73as s98ih9t
14 Oct 16
Draft registration statement
12:00am
F-1
EX-10.1
k6wgg4n7ayvyo6h1sh
30 Dec 16
Registration statement (foreign)
12:00am
F-1
EX-10.2
bvgc69
30 Dec 16
Registration statement (foreign)
12:00am